AML/CFT. The Company shall and shall ensure that each of its Key Subsidiaries shall institute, maintain and comply with internal policies, procedures and controls for AML/CFT consistent with its business and customer profile, in compliance with national laws and regulations, and in furtherance of applicable international AML/CFT best practices.
AML/CFT. 15. The Company maintains a Anti-Money Laundering and Countering the Financing of Terrorism (AML/CFT) Policy. The Company aims to reasonably identify each prospective purchaser of Tokens, by cross-checking user data against government watch lists, as well as third-party identity verification and authentication services to ensure that the Purchaser is not a Restricted Person. If the Purchaser is flagged through the Company’s internal controls, the latter may require from the Purchaser an additional proof of identification. The Company reserves the right to deny permit to any purchases of the Purchaser until additional and verifiable proof of identity is received and the Purchaser has been approved as a prospective purchaser.
AML/CFT. At least one of the following: (i) a report by the AML/CFT Officer on the implementation of, and compliance with, the Borrower’s AML/CFT policies, procedures and controls; (ii) an internal or external auditor’s assessment on the adequacy of the Borrower’s policies, procedures and controls for AML/CFT; or (iii) a report by the AML/CFT regulator of the Borrower concerning the Borrower’s compliance with local AML/CFT laws and regulations; FORM OF PORTFOLIO REPORT (See Section 5.04 (b) of the Loan Agreement) Bank Name: Date of Financial Year Ending (dd/mm/yy) Exchange Rate (Local Currency/US$) Portfolio >90 days Portfolio overdue Annual Disbursements Outstanding Outstanding Total Disbursed Loan Type Number Balance (US$) Number Balance (US$) Number FY ____ (US$) Consumer Housing Loans Other Consumer Commercial Loans (MSME & Corporate) <US$1,000 <US$5,000 <US$10,000 <US$100,000 <US$1 million <US$2 million >US$2 million Total Portfolio Comments: Guidelines for Completing this Table • Provide data as of the final day of the financial institution’s financial year unless otherwise specified. • Provide data in Dollars, using the exchange rate (Pesos/ $) at the end of the financial institution’s financial year if applicable. • It is important that the table be filled in exactly as it is presented above, using the pre-established loan size categories as IFC will be aggregating data across clients and requires this for comparability. • Loans should be put into loan type categories based on the size of the loan at origination. • For overdue loans please report total loan amounts outstanding for which payments have not been made (and not just the overdue portion). • Do not include penalties and fees in the outstanding balances. • Loans to individuals for business purposes should be included in commercial loans, not consumer loans. • Disbursements should include all loans disbursed over the course of the year. Where loans are disbursed in tranches over two financial year periods, please include the full disbursement amount in the year of the first disbursement. • Please provide comments on any unusual aspects of the date in this table, or aberrations from these guidelines. SCHEDULE 11 FORM OF S&E PERFORMANCE REPORT (See Section 5.04 (d) of the Loan Agreement) Please provide responses to the questions below. Please include additional sheets or attachments as required to provide details on questions that have been answered Yes. Name of Organization Completed by (name): Posit...
AML/CFT. Promptly notify the Trustee and/ or the Original Debentureholder in writing upon becoming aware (a) that the Issuer is not in compliance with applicable Law or regulation concerning AML/ CFT; (b) that any Authority has requested, through an action plan or any other manner, that the Issuer amend, change, improve or supplement any part of its AML/ CFT policies, procedures or controls; or (c) of the existence of any legal, regulatory, administrative or criminal investigation, proceeding or fine in which it is alleged (A) that any part of the Issuer’s AML/ CFT policies, procedures, operations or controls are deficient, or (B) that the Issuer or any of its employees, board members or Affiliates have violated applicable law or regulation concerning AML/ CFT.
